XML 34 R5.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Changes in Equity - BRL (R$)
R$ in Thousands
Total
Share capital
Equity instrument granted
Capital reserve
Treasury shares
Revaluation reserve on subsidiaries
Legal Reserves
Investments statutory reserve
Valuation Adjustments
Cumulative translation adjustments
Retained earnings
Additional dividends to the minimum mandatory dividends
Shareholders of the Company
Non-controlling interests in subsidiaries
Beginning balance at Dec. 31, 2018 R$ 9,800,029 R$ 5,171,752 R$ 4,309 R$ 542,400 R$ (485,383) R$ 4,712 R$ 686,665 R$ 3,412,427 R$ (63,989) R$ 65,857 R$ 109,355 R$ 9,448,105 R$ 351,924
Net income for the year 402,944 373,526 373,526 29,418
Other comprehensive income:                            
Fair value adjustments of available for financial instruments, net of income taxes (52,297)               (52,318)       (52,318) 21
Actuarial gain (loss) of post-employment benefits, net of income taxes (36,787) (30,010) (30,010) (6,777)
Currency translation of foreign subsidiaries and the effect of net investments hedge, net of income taxes 36,570 36,570 36,570
Total comprehensive income for the year 350,430 (82,328) 36,570 373,526 327,768 22,662
Equity instrument granted of subsidiaries 7,661 7,661 7,661
Shareholder transaction - gain in reimbursement of shares pref. B from Oxiteno Nordeste 1,489 1,489 (1,489)
Realization of revaluation reserve of subsidiaries (190) 190
Income and social contribution taxes on realization of revaluation reserve of subsidiaries (31) (31) (31)
Transfer to statutory reserve 1,648 (1,648)
Dividends attributable to non-controlling interests (993) (993)
Redemption of non-controlling shares of Oxiteno Nordeste (2,180) (2,180)
Capital increase from Iconic non-controlling shareholders 6,996 6,996
Approval of additional dividends by the Shareholders' Meeting (109,355) (109,355) (109,355)
Allocation of net income:                            
Legal reserve 18,676 (18,676)
Proposed dividends (R$ 0.20 per share) (124,002) (137,468) 261,470
Intermediary dividends (217,382) (217,382) (217,382)
Ending balance at Dec. 31, 2019 9,835,175 5,171,752 11,970 542,400 (485,383) 4,522 705,341 3,290,073 (146,317) 102,427 261,470 9,458,255 376,920
Net income for the year 927,697 893,383 893,383 34,314
Other comprehensive income:                            
Fair value adjustments of available for financial instruments, net of income taxes (313,081) (313,081) (313,081)
Actuarial gain (loss) of post-employment benefits, net of income taxes (16,887) (5,592) (5,592) (11,295)
Currency translation of foreign subsidiaries and the effect of net investments hedge, net of income taxes 129,169 129,169 129,169
Total comprehensive income for the year 726,898 (318,673) 129,169 893,383 703,879 23,019
Issuance of shares related to the subscription warrants - indemnification - Extrafarma acquisition 54,763 54,763 54,763
Stock plan (6,799) (3,114) (3,685) (6,799)
Equity instrument granted 4,526 4,526 4,526
Equity instrument granted of subsidiaries 5,908 5,908 5,908
Income and social contribution taxes on realization of revaluation reserve of subsidiaries (185) 185
Transfer to statutory reserve (774) 774
Shareholder transaction – changes of investments 42 42 (42)
Dividends attributable to non-controlling interests (24,379) (1,001) (23,378)
Approval of additional dividends by the Shareholders' Meeting (261,470) (261,470) (261,470)
Allocation of net income:                            
Legal reserve 44,669 (44,669)
Investments statutory reserve 368,966 (368,966)
Proposed dividends (R$ 0.20 per share) (424,357) (479,748) 55,391 (424,357)
Ending balance at Dec. 31, 2020 9,910,265 5,171,752 22,404 594,049 (489,068) 4,337 750,010 3,658,265 (464,990) 231,596 55,391 9,533,746 376,519
Net income for the year 883,878 850,463 850,463 33,415
Other comprehensive income:                            
Fair value adjustments of available for financial instruments, net of income taxes 7,274 7,304 7,304 (30)
Actuarial gain (loss) of post-employment benefits, net of income taxes 46,610 35,548 35,548 11,062
Currency translation of foreign subsidiaries and the effect of net investments hedge, net of income taxes 73,049 73,049 73,049
Total comprehensive income for the year 1,010,811 42,852 73,049 850,463 966,364 44,447
Issuance of shares related to the subscription warrants - indemnification - Extrafarma acquisition 1,819 1,819 1,819
Equity instrument granted 9,264 8,008 613 643 9,264
Equity instrument granted of subsidiaries 3,631 3,631 3,631
Realization of revaluation reserve of subsidiaries (183) 183
Transfer to statutory reserve 11,641 (11,641)
Unclaimed dividends forfeited 11,816 10,487 10,487 1,329
Dividends attributable to non-controlling interests (19,005) 971 (19,976)
Approval of additional dividends by the Shareholders' Meeting (55,391) (55,391) (55,391)
Allocation of net income:                            
Legal reserve 42,523 (42,523)
Investments statutory reserve 403,970 (403,970)
Proposed dividends (R$ 0.20 per share) (185,896) (185,896) (185,896)
Intermediary dividends (218,074) (218,074) (218,074)
Ending balance at Dec. 31, 2021 R$ 10,469,240 R$ 5,171,752 R$ 34,043 R$ 596,481 R$ (488,425) R$ 4,154 R$ 792,533 R$ 4,073,876 R$ (422,138) R$ 304,645 R$ 10,066,921 R$ 402,319